Vericel Corporation filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the three and nine months ended September 30, 2026, reporting net income of $14,161 thousand for the third quarter and net product sales of $85,371 thousand.
Key Highlights
- Q3 2026 net product sales: $85,371 thousand, compared to $67,503 thousand in Q3 2025.
- Q3 2026 net income: $14,161 thousand, or $0.27 diluted earnings per share, versus net income of $5,074 thousand, or $0.10 diluted, in Q3 2025.
- Nine-month net income: $10,065 thousand for the nine months ended September 30, 2026, compared to a net loss of $(6,725) thousand for the same period in 2025.
- Total assets: $517,110 thousand as of September 30, 2026, up from $487,969 thousand at December 31, 2025.
- Cash and cash equivalents: $133,493 thousand as of September 30, 2026, compared to $100,092 thousand at December 31, 2025.
- Share repurchase: 221 thousand shares were repurchased and retired during Q3 2026 for $8,847 thousand.
- Shares outstanding: 51,029,770 shares of common stock as of October 29, 2026.
Vericel Reports Q3 2026 Operating Income and Nine-Month Profit Swing
According to the filing, Vericel Corporation (NASDAQ:VCEL) reported third-quarter 2026 net product sales of $85,371 thousand, an increase from $67,503 thousand in the same quarter of 2025. Gross profit for Q3 2026 was $62,610 thousand, compared to $49,585 thousand in Q3 2025. Income from operations reached $12,186 thousand in Q3 2026, up from $3,450 thousand in Q3 2025. Total other income for the quarter was $1,975 thousand, which included interest income of $2,152 thousand and interest expense of $(160) thousand.
For the nine months ended September 30, 2026, the company disclosed net product sales of $231,253 thousand versus $183,341 thousand in the prior-year period. The nine-month income from operations was $4,556 thousand, compared to a loss from operations of $(11,371) thousand in the nine months ended September 30, 2025. Net income for the nine-month period was $10,065 thousand, or $0.19 diluted earnings per share, against a net loss of $(6,725 thousand), or $(0.13) per share, in the comparable 2025 period.
The condensed consolidated balance sheet as of September 30, 2026 showed total shareholders' equity of $384,172 thousand, up from $354,640 thousand at December 31, 2025. The accumulated deficit narrowed to $(366,232) thousand from $(376,297) thousand over the same period. During Q3 2026, the company repurchased and retired 221 thousand shares for $8,847 thousand, according to the shareholders' equity statement. Research and development expenses for the nine months ended September 30, 2026 were $22,482 thousand, while selling, general and administrative expenses were $141,240 thousand.
What Was Disclosed
Vericel Corporation's Form 10-Q for the quarter ended September 30, 2026 disclosed quarterly net product sales of $85,371 thousand, net income of $14,161 thousand, total assets of $517,110 thousand, and a share repurchase of 221 thousand shares for $8,847 thousand during the quarter.




Please wait processing your request...